Company news

Mannkind Corporation (NASDAQ:MNKD) news

Mannkind Corporation news releases on 6ix. Latest, Sep 9, 2026: MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled…

Mannkind Corporation (NASDAQ:MNKD) news

Press releases & updates

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

MannKind Announces $50 Million Private Placement

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind to Present at Jefferies Global Healthcare Conference

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

MannKind Announces Settlement of Convertible Senior Notes

MannKind to Participate in Upcoming Investor Conferences

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

MannKind Provides Business Updates and 2026 Growth Drivers

MannKind Shares FUROSCIX® Business Updates

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

MannKind to Present at the Jefferies Global Healthcare Conference

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

MannKind to Present at Upcoming Investor Conferences

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

MannKind Expands Executive Leadership Team